Relmada Therapeutics(RLMD) - 2025 Q2 - Quarterly Results

CORAL GABLES, FL – Aug 7, 2025 (GlobeNewswire) – Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada" or the "Company"), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today reported financial results for the second quarter ended June 30, 2025, announced 6-month follow-up data from the Phase 2 study of NDV-01 in bladder cancer and provided a corporate and pipeline update. Highlights of the 6-month follow-up data from the Phas ...